R&D of Chinese medicine lacks the input of the whole country as a large enterprise in Europe and America
The business agency reported on April 15th that the reporter recently investigated the traditional Chinese medicine industry in Beijing, Tianjin, Guangdong, and other places. It was learned that in recent years, some outstanding traditional Chinese medicine companies have insisted on scientific and technological innovation, which has given birth to new vitality and vitality for the Chinese medicine industry in China. With the use of factors such as decentralization and difficult transformation of results, the technological innovation in the Chinese medicine industry has become very weak. At the same time, foreign traditional Chinese medicines have seized the “nose of the nose†of technological innovation and competed to catch up, which has directly led to a trade deficit for three consecutive years between the export of proprietary Chinese medicines and the import of Chinese herbal medicines in China. Industry experts strongly urge that strengthening scientific and technological innovation is related to the overall development of Sinopharm in the future. It should adopt a series of positive measures such as the formation of a national technical team, the establishment of a public service platform, and the centralized use of support funds as soon as possible to effectively consolidate and strengthen the market position of Sinopharm.
Scientific and technological innovation has given birth to new vitality Reporter's investigation found that in recent years, national and local governments have attached great importance to the innovation of traditional Chinese medicine science and technology, and adopted policy guidance to encourage enterprises to carry out scientific and technological innovation. Some outstanding Chinese medicine companies have the courage to innovate in science and technology, general refinement, ancient recovery, and dosage form transformation. The development of new drugs has changed the original crude black image of traditional Chinese medicine and developed a batch of new Chinese medicine that can meet the needs of TCM syndrome differentiation and treatment, maintain or exceed the efficacy of traditional Chinese medicine decoction, and can carry and take convenience. The vitality and vitality of Sinopharm.
Tianjin Tasly Group Co., Ltd. is an excellent company that has rapidly grown up to implement the modernization of traditional Chinese medicine. According to Zhu Yonghong, a special assistant to the chairman of the company, the company annually invests as much as 13% of its sales revenue in research. This is also very rare in domestic Chinese medicine companies. The company has also built more than 300 scientific research teams. Tasly has applied for more than 1,000 patent applications and has undertaken many major national scientific research projects. The company has achieved rapid development due to technological innovation.
Scientific and technological innovation has also brought vitality to the 100-year-old Chinese medicine companies. Tianjin Darentang Pharmaceutical Factory has always maintained a good momentum of development based on inherited and innovative two-wheel drive. The factory first took HuXianghengqi Pills into capsules in the Chinese herbal medicine industry, which not only changed traditional Chinese medicine pill formulations that are difficult for Chinese medicine to break through, but also preserved traditional Chinese medicines' active ingredients better and improved their efficacy. The factory also boldly made scientific research and innovation and focused on the heart. Major diseases such as cerebrovascular diseases, digestive diseases, and tumors were treated with traditional Chinese medicines and proprietary Chinese medicines such as Niuhuang Jiangya Pills and Shengmai Pills were developed, and good curative effects were achieved. In order to change the situation of hand-made and difficult-to-control quality, Da Rentang took the lead. Renewing the production and packaging equipment of traditional Chinese medicines has achieved a transformation from manual production to mechanized production. At present, this old brand is the only Chinese medicine unit formulated with the green standard for proprietary Chinese medicines in the country.
Technological innovation has also revived some Chinese medicine companies. Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. has now become the largest monomeric proprietary Chinese medicine company in South China, but it was heavily indebted and suffered serious losses 10 years ago. Wang Deqin, deputy general manager of the company, told reporters that it is technological innovation that has brought the company back to life. The company will carry out scientific and technological innovations such as compound Danshen tablets and Banlangen to achieve a new system of generic drugs and refinement of generic drugs. The sales volume has soared from 20 million in the current year to 50 million today, not only turning losses into profits but also becoming bigger and stronger.
The more obstacles to innovation, the shouting of corporate power Although technological innovation has given rise to the vitality and vitality of the Chinese medicine industry, the technological innovation of the Chinese medicine industry is still very weak due to factors such as the lack of investment, the scattered use of funds, and the difficult transformation of results.
Insufficient investment. Wang Huankui, executive vice president of the Guangzhou Pharmaceutical Industry Association, pointed out that the pharmaceutical companies' funds for technological innovation are either stretched or are reluctant to invest. Foreign pharmaceutical companies invest 15 to 20% of the annual sales of scientific research. However, Chinese medicine companies' investment in scientific research falls far short of such ratio, or even negative input, which has led to significant scientific research in Chinese medicine. The results are very small, but also make Chinese medicine companies lack of competitiveness. “Imagine that our entire country has invested less in research and development of traditional Chinese medicine than in large European and American companies.†Reporters surveyed numerous companies and found that there are not a lot of Chinese companies investing in technology research and development. Even if they do, their investment only accounts for sales revenue. 3-5%.
“The main reason why we are reluctant to invest in pharmaceuticals is that drug R&D is a process with many investments, long periods, and high risks. It may invest huge amounts of money and spend years, and it may not be able to develop a new drug. Difficulties in making Chinese companies that have insufficient capital strength are even more reluctant to make long-term sustained investments, said Zheng Yongfeng, legal director of Tianjin Tasly Group.
Decentralized use of funds. Zhang Junxiu, president of the Guangdong Pharmaceutical Industry Association, believes that in order to support the technological innovation of Chinese medicine companies, in recent years, the state and local governments have invested a considerable amount in supporting funds, but they have not played a significant boost. The reason is that the limited distribution of funds to support the use of scattered, "Sprinkle noodles" effect puzzled. "The state should focus its funds on the selection of support for the development of advantageous products."
The results are difficult to translate. The difficulty in transforming scientific and technological achievements into productive forces is also the confusion faced by TCM science and technology innovation. Wang Deqin, deputy general manager of Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd., told reporters that because of the peculiarities of the pharmaceutical industry, it is strictly controlled by the state, and the long process and complicated procedures for approval of new drugs have often delayed the time for turning scientific research achievements into productivity. .
Talent is easier to lose. The main body of scientific and technological innovation in Chinese medicine is the enterprise, but the internal and external environment that enterprises face is often difficult to retain talent. Wang Deqin, for example, told the reporter that the evaluation system for corporate talents currently adopted in society still uses the university system and publishes papers to assess professional titles. However, after the same doctor graduated from a company or university, the wages and benefits received are very different. . This has led to the loss of high-end talent from companies, and the lack of corporate science and technology talent.
Build incubators to enhance competitiveness The reporter has learned that according to the national industrial development plan, the next decade is a golden decade for the development of the pharmaceutical industry, and pharmaceutical companies at home and abroad are seizing opportunities. However, due to the soft underbelly of scientific and technological innovation, the use of foreign traditional Chinese medicines to display their superiority in scientific research has shown a trend of catching up with Chinese medicine.
According to statistics, in 2010, China's proprietary Chinese medicines reached 411 million U.S. dollars, an increase of 21% year-on-year. Among them, exports of 193 million US dollars, an increase of 18.05%; imports of 218 million US dollars, an increase of 23.71%. The Chinese patent medicine trade continued to have an export deficit since 2008, and the deficit increased in 2010.
According to Liu Juyan, a member of the National Pharmacopoeia Formulation Expert Group, this means that, from the perspective of market share and growth rate, foreign traditional Chinese medicines have shown more advantages than Chinese medicines in terms of market competitiveness. In recent years, the biggest weapon of foreign medicine has been to win. Perseverance in technological innovation.
People in the industry strongly urge that in order to seize the development opportunities of the Chinese medicine industry, the government and enterprises should attach great importance to scientific and technological innovation.
Form a national technical team. At present, the innovation of traditional Chinese medicine companies depends on their own organizational strength, and researchers are often scattered in different research institutes, and it is difficult to form a joint force. This situation cannot meet the needs of modernization of traditional Chinese medicine.
Establish a public service platform. Many companies have called for the government to establish a platform for enterprises to provide public services for Chinese medicine scientific research and technology, pool social resources, reduce the burden on enterprises, and share research results.
National policy tilts support. Ouyang Qiang, chairman of Guangzhou Liji Pharmaceutical Co., Ltd., pointed out that drug science and technology R&D is a long and complicated systematic project, and it needs to be supported by the government's full range of policies. Otherwise, it will be abandoned halfway and all efforts will be abandoned.
Scientific and technological innovation has given birth to new vitality Reporter's investigation found that in recent years, national and local governments have attached great importance to the innovation of traditional Chinese medicine science and technology, and adopted policy guidance to encourage enterprises to carry out scientific and technological innovation. Some outstanding Chinese medicine companies have the courage to innovate in science and technology, general refinement, ancient recovery, and dosage form transformation. The development of new drugs has changed the original crude black image of traditional Chinese medicine and developed a batch of new Chinese medicine that can meet the needs of TCM syndrome differentiation and treatment, maintain or exceed the efficacy of traditional Chinese medicine decoction, and can carry and take convenience. The vitality and vitality of Sinopharm.
Tianjin Tasly Group Co., Ltd. is an excellent company that has rapidly grown up to implement the modernization of traditional Chinese medicine. According to Zhu Yonghong, a special assistant to the chairman of the company, the company annually invests as much as 13% of its sales revenue in research. This is also very rare in domestic Chinese medicine companies. The company has also built more than 300 scientific research teams. Tasly has applied for more than 1,000 patent applications and has undertaken many major national scientific research projects. The company has achieved rapid development due to technological innovation.
Scientific and technological innovation has also brought vitality to the 100-year-old Chinese medicine companies. Tianjin Darentang Pharmaceutical Factory has always maintained a good momentum of development based on inherited and innovative two-wheel drive. The factory first took HuXianghengqi Pills into capsules in the Chinese herbal medicine industry, which not only changed traditional Chinese medicine pill formulations that are difficult for Chinese medicine to break through, but also preserved traditional Chinese medicines' active ingredients better and improved their efficacy. The factory also boldly made scientific research and innovation and focused on the heart. Major diseases such as cerebrovascular diseases, digestive diseases, and tumors were treated with traditional Chinese medicines and proprietary Chinese medicines such as Niuhuang Jiangya Pills and Shengmai Pills were developed, and good curative effects were achieved. In order to change the situation of hand-made and difficult-to-control quality, Da Rentang took the lead. Renewing the production and packaging equipment of traditional Chinese medicines has achieved a transformation from manual production to mechanized production. At present, this old brand is the only Chinese medicine unit formulated with the green standard for proprietary Chinese medicines in the country.
Technological innovation has also revived some Chinese medicine companies. Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. has now become the largest monomeric proprietary Chinese medicine company in South China, but it was heavily indebted and suffered serious losses 10 years ago. Wang Deqin, deputy general manager of the company, told reporters that it is technological innovation that has brought the company back to life. The company will carry out scientific and technological innovations such as compound Danshen tablets and Banlangen to achieve a new system of generic drugs and refinement of generic drugs. The sales volume has soared from 20 million in the current year to 50 million today, not only turning losses into profits but also becoming bigger and stronger.
The more obstacles to innovation, the shouting of corporate power Although technological innovation has given rise to the vitality and vitality of the Chinese medicine industry, the technological innovation of the Chinese medicine industry is still very weak due to factors such as the lack of investment, the scattered use of funds, and the difficult transformation of results.
Insufficient investment. Wang Huankui, executive vice president of the Guangzhou Pharmaceutical Industry Association, pointed out that the pharmaceutical companies' funds for technological innovation are either stretched or are reluctant to invest. Foreign pharmaceutical companies invest 15 to 20% of the annual sales of scientific research. However, Chinese medicine companies' investment in scientific research falls far short of such ratio, or even negative input, which has led to significant scientific research in Chinese medicine. The results are very small, but also make Chinese medicine companies lack of competitiveness. “Imagine that our entire country has invested less in research and development of traditional Chinese medicine than in large European and American companies.†Reporters surveyed numerous companies and found that there are not a lot of Chinese companies investing in technology research and development. Even if they do, their investment only accounts for sales revenue. 3-5%.
“The main reason why we are reluctant to invest in pharmaceuticals is that drug R&D is a process with many investments, long periods, and high risks. It may invest huge amounts of money and spend years, and it may not be able to develop a new drug. Difficulties in making Chinese companies that have insufficient capital strength are even more reluctant to make long-term sustained investments, said Zheng Yongfeng, legal director of Tianjin Tasly Group.
Decentralized use of funds. Zhang Junxiu, president of the Guangdong Pharmaceutical Industry Association, believes that in order to support the technological innovation of Chinese medicine companies, in recent years, the state and local governments have invested a considerable amount in supporting funds, but they have not played a significant boost. The reason is that the limited distribution of funds to support the use of scattered, "Sprinkle noodles" effect puzzled. "The state should focus its funds on the selection of support for the development of advantageous products."
The results are difficult to translate. The difficulty in transforming scientific and technological achievements into productive forces is also the confusion faced by TCM science and technology innovation. Wang Deqin, deputy general manager of Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd., told reporters that because of the peculiarities of the pharmaceutical industry, it is strictly controlled by the state, and the long process and complicated procedures for approval of new drugs have often delayed the time for turning scientific research achievements into productivity. .
Talent is easier to lose. The main body of scientific and technological innovation in Chinese medicine is the enterprise, but the internal and external environment that enterprises face is often difficult to retain talent. Wang Deqin, for example, told the reporter that the evaluation system for corporate talents currently adopted in society still uses the university system and publishes papers to assess professional titles. However, after the same doctor graduated from a company or university, the wages and benefits received are very different. . This has led to the loss of high-end talent from companies, and the lack of corporate science and technology talent.
Build incubators to enhance competitiveness The reporter has learned that according to the national industrial development plan, the next decade is a golden decade for the development of the pharmaceutical industry, and pharmaceutical companies at home and abroad are seizing opportunities. However, due to the soft underbelly of scientific and technological innovation, the use of foreign traditional Chinese medicines to display their superiority in scientific research has shown a trend of catching up with Chinese medicine.
According to statistics, in 2010, China's proprietary Chinese medicines reached 411 million U.S. dollars, an increase of 21% year-on-year. Among them, exports of 193 million US dollars, an increase of 18.05%; imports of 218 million US dollars, an increase of 23.71%. The Chinese patent medicine trade continued to have an export deficit since 2008, and the deficit increased in 2010.
According to Liu Juyan, a member of the National Pharmacopoeia Formulation Expert Group, this means that, from the perspective of market share and growth rate, foreign traditional Chinese medicines have shown more advantages than Chinese medicines in terms of market competitiveness. In recent years, the biggest weapon of foreign medicine has been to win. Perseverance in technological innovation.
People in the industry strongly urge that in order to seize the development opportunities of the Chinese medicine industry, the government and enterprises should attach great importance to scientific and technological innovation.
Form a national technical team. At present, the innovation of traditional Chinese medicine companies depends on their own organizational strength, and researchers are often scattered in different research institutes, and it is difficult to form a joint force. This situation cannot meet the needs of modernization of traditional Chinese medicine.
Establish a public service platform. Many companies have called for the government to establish a platform for enterprises to provide public services for Chinese medicine scientific research and technology, pool social resources, reduce the burden on enterprises, and share research results.
National policy tilts support. Ouyang Qiang, chairman of Guangzhou Liji Pharmaceutical Co., Ltd., pointed out that drug science and technology R&D is a long and complicated systematic project, and it needs to be supported by the government's full range of policies. Otherwise, it will be abandoned halfway and all efforts will be abandoned.
One-time Use Tourniquet Volume
Nurse Tourniquet,Tourniquet First Aid,Quick Release Tourniquet,Tourniquet For Bleeding Control
GUANGDONG JIANGMEN RONGHAI MEDICAL TECHNOLOGY CO.,LTD , https://www.kimaomedical.com